SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hagberg Oskar)
 

Sökning: WFRF:(Hagberg Oskar) > Adjuvant chemothera...

  • Hall, Kirsten SundbyOslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital (författare)

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • ELSEVIER SCI LTD,2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-360179
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-360179URI
  • https://doi.org/10.1016/j.ejca.2018.05.011DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:138664185URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-149842URI
  • https://lup.lub.lu.se/record/4c4eb951-eb77-4b3d-8e13-d9173093a3d0URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Swedish Cancer Society; National Advisory Unit for Sarcoma in Norway
  • Purpose: To investigate the outcome following adjuvant doxorubicin and ifosfamide in a prospective non-randomised study based on a soft tissue sarcoma (STS) patient subgroup defined by specific morphological characteristics previously shown to be at a high-risk of metastatic relapse. The expected 5-year cumulative incidence of metastases in patients with this risk profile has previously been reported to be about 50% without adjuvant chemotherapy.Methods: High-risk STS was defined as high-grade morphology (according to the Federation Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade II-III) and either vascular invasion or at least two of the following criteria: tumour size >= 8.0 cm, infiltrative growth and necrosis. Six cycles of doxorubicin (60 mg/m(2)) and ifosfamide (6 g/m(2)) were given. Postoperative accelerated radiotherapy was applied and scheduled between cycles 3 and 4.Results: For the 150 eligible patients, median follow-up time for metastases-free survival was 3.9 years (range 0.2-8.7). Five-year metastases-free survival (MFS) was 70.4% (95% confidence interval [CI]: 63.1-78.4) with a local recurrence rate of 14.0% (95% CI: 7.8-20.2). For overall survival (OS), the median follow-up time was 4.4 years (range: 0.2-8.7). The five-year OS was 76.1% (95% CI: 68.8-84.2). Tumour size, deep location and reduced dose intensity (<80%) had a negative impact on survival. Toxicity was moderate with no treatment-related death.Conclusions: A benefit of adjuvant chemotherapy, compared to similar historical control groups, was demonstrated in STS patients with defined poor prognostic factors. Vascular invasion, tumour size, growth pattern and necrosis may identify patients in need of adjuvant chemotherapy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bruland, Oyvind S.Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway;Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway,Oslo university hospital,Norwegian Radium Hospital,University of Oslo (författare)
  • Bjerkehagen, BodilOslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway,Norwegian Radium Hospital,Oslo university hospital (författare)
  • Zaikova, OlgaOslo Univ Hosp, Div Orthopaed Surg, Oslo, Norway,Oslo university hospital (författare)
  • Engellau, JacobLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-jen (författare)
  • Hagberg, OskarReg Canc Ctr South, Lund, Sweden,Skåne University Hospital(Swepub:lu)mats-oha (författare)
  • Hansson, LinaSahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden,Sahlgrenska University Hospital (författare)
  • Hagberg, HansKarolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi,Uppsala Univ Hosp, Sweden,Uppsala University Hospital(Swepub:uu)hanshagb (författare)
  • Ahlstrom, MarieLund Univ, Lund, Sweden;Skane Univ Hosp, Dept Oncol, Lund, Sweden,Lund University,Skåne University Hospital (författare)
  • Knobel, HeidiSt Olavs Univ Hosp, Dept Oncol, Trondheim, Norway,St. Olav’s University Hospital (författare)
  • Papworth, KarinNorrlands Univ Hosp, Dept Oncol, Umea, Sweden,Norrland University Hospital (författare)
  • Zemmler, MajaLinkoping Univ Hosp, Dept Oncol, Linkoping, Sweden,Region Östergötland, Onkologiska kliniken US,Linköping University Hospital(Swepub:liu)n/a (författare)
  • Goplen, DorotaHaukeland Hosp, Dept Musculoskeletal Tumour Serv Oncol, Bergen, Norway,Haukeland University Hospital (författare)
  • Bauer, Henrik C. F.Karolinska Institute (författare)
  • Eriksson, MikaelLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-mer (författare)
  • Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, NorwayOslo university hospital (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Journal of Cancer: ELSEVIER SCI LTD99, s. 78-850959-80491879-0852

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy